Report
US-China Biomedical Technology Inc
2 Park Plz Ste 400
Phone: (949) 679-3992p:949 679-3992 IRVINE, CA  92614-8514  United States Fax: (949) 398-5384f:949 398-5384

This company is no longer actively traded on any major stock exchange.


SEC Issues Order Involving U.S.-China Biomedical Technology


WASHINGTON, June 12 -- The Securities and Exchange Commission issued the following order (Admin. Proc. File No. 3-20306) involving U.S.-China Biomedical Technology:

In the Matter of U.S.-CHINA BIOMEDICAL TECHNOLOGY, INC.

ORDER TO SHOW CAUSE

The Securities and Exchange Commission ("Commission") issued an Order Instituting Proceedings ("OIP") on May 13, 2021, pursuant to Section 12(j) of the Securities Exchange Act of 1934, against respondent U.S.-China Biomedical Technology, Inc. ("Respondent")./1

On June 2, 2021, the Division of Enforcement filed a Declaration of Sandhya C. Harris, which established that, pursuant to Commission Rule of Practice 141(a)(2)(ii),/2 service of the OIP was made on Respondent on May 18, 2021.

As stated in the OIP, Respondent's answer was required to be filed within ten days of the service of the OIP./3

As of the date of this order, Respondent has not filed an answer. The prehearing conference and hearing are thus continued indefinitely.

Accordingly, Respondent is ORDERED to SHOW CAUSE by June 25, 2021, why the registration of its securities should not be revoked by default due to its failure to file an answer and to otherwise defend this proceeding. When a party defaults, the allegations in the OIP will be deemed to be true and the Commission may determine the proceeding against that party upon consideration of the record without holding a public hearing.

If Respondent fails to respond to this order to show cause, it may be deemed in default, the proceeding may be determined against it, and the registration of its securities may be revoked./4

Upon review of the filings in response to this order, the Commission will either direct further proceedings by subsequent order or issue a final order resolving the matter.

The parties' attention is called to the Commission's March 18, 2020 order regarding the filing and service of papers, which provides that pending further order of the Commission parties to the extent possible shall submit all filings electronically at apfilings@sec.gov./5

Also, the Commission's Rules of Practice were recently amended to include new e-filing requirements, which took effect on April 12, 2021./6

For the Commission, by the Office of the General Counsel, pursuant to delegated authority.

Vanessa A. Countryman, Secretary

* * *

Footnotes:

1/ U.S.-China Biomedical Tech., Inc., Exchange Act Release No. 91889, 2021 WL 1944723 (May 13, 2021).

2/ 17 C.F.R. Sec. 201.141(a)(2)(ii).

3/ U.S.-China Biomedical Tech., Inc., 2021 WL 1944723, at *2; Rules of Practice 151(a), 160(b), 220(b), 17 C.F.R. Sec.Sec. 201.151(a), 201.160(b), 201.220(b).

4/ Rules of Practice 155, 180, 17 C.F.R. Sec.Sec. 201.155, 201.180; see U.S.-China Biomedical Tech., Inc., 2021 WL 1944723, at *2 ("If Respondent fails to file the directed Answer, . . . [it] may be deemed in default and the proceedings may be determined against [it] . . . .").

5/ Pending Administrative Proceedings, Exchange Act Release No. 88415, 2020 WL 1322001 (Mar. 18, 2020), https://www.sec.gov/litigation/opinions/2020/33-10767.pdf.

6/ Amendments to the Commission's Rules of Practice, Exchange Act Release No. 90442, 2020 WL 7013370 (Nov. 17, 2020), 85 Fed. Reg. 86,464, 86,474 (Dec. 30, 2020); Instructions for Electronic Filing and Service of Documents in SEC Administrative Proceedings and Technical Specifications, https://www.sec.gov/efapdocs/instructions.pdf. The amendments also impose other obligations on parties to administrative proceedings such as a new redaction and omission of sensitive personal information requirement. Amendments to the Commission's Rules of Practice, 85 Fed. Reg. at 86,465-81.


Related Businesses
- - Customer

Copyright © 2024 by CreditRiskMonitor.com (Ticker: CRMZ®). All rights reserved.  You are not permitted to use this report or the information contained herein for any purpose not expressly permitted by CreditRiskMonitor.com, Inc. Except as expressly permitted by CreditRiskMonitor.com, Inc., you are not permitted, in whole or in part, to copy, alter, correct, adapt, translate, enhance, lease, sell, sublicense, assign, distribute, publish, otherwise make available to any third party, or prepare derivative works or improvements of this report or any of the information contained therein. You are not permitted to reverse engineer, disassemble, decompile, decode, or adapt the software, algorithms or other processes used to prepare this report, or otherwise attempt to derive or gain access to the source code of same. You agree not to remove, alter, obscure, combine or otherwise change any disclaimers, trademarks, copyrights, other intellectual property rights, proprietary rights, or other symbols, notices, marks, or serial numbers on or relating to any copy of the report or on marketing or other materials that CreditRiskMonitor.com, Inc. may provide to you. You will not use this report in any manner or for any purpose that infringes, misappropriates, or otherwise violates any right of any party, or that violates any applicable law.  
The FRISK® scores, agency ratings, credit limit recommendations and other scores, analysis and commentary are opinions of CreditRiskMonitor.com, Inc. and/or its suppliers, not statements of fact, and should be one of several factors in making credit decisions.  Any reliance you place on the information in this report is strictly at your own risk. Except as expressly provided by CreditRiskMonitor.com, Inc., no warranties or representations of any type, including without limitation of results to be obtained, merchantability or fitness for a particular purpose, are made concerning any part of CreditRiskMonitor.com, Inc.’s service, including without limitation the FRISK® scores.  The information published above has been obtained from sources CreditRiskMonitor considers to be reliable.  CreditRiskMonitor.com, Inc. and its third-party suppliers do not guarantee or validate the accuracy and completeness of the information provided in this report, the underlying information input to create the FRISK® scores, and specifically do not assume responsibility for not reporting any information omitted or withheld.  By using this website, you accept the Terms of Use Agreement
Contact Us: 845.230.3000
Fundamental financial data concerning public companies may be provided by Refinitiv (click for restrictions)
Thursday, March 28, 2024